Matica Biotechnology, the U.S. cell and gene therapy (CGT) contract development and manufacturing (CDMO) subsidiary of CHA Biotech, will team up with U.S. biotech company VaxDome to co-develop an antiviral hybrid vaccine.
An antiviral hybrid vaccine is a universal vaccine technology that can respond to various mutant viruses. It is being developed to address the limitation of existing vaccines that use specific viral antigens and must redesign those antigens when new variants emerge.
CHA Biotech said on the 7th that Matica Biotechnology, in collaboration with VaxDome, will push for clinical entry of an antigen-independent antiviral hybrid vaccine candidate.
Matica Biotechnology will handle process development (PD), analytical method development (AD), and production of clinical active pharmaceutical ingredients. It plans to support everything from process development to clinical manufacturing using a range of viral vector platforms, including retrovirus (RV), lentivirus (LV), and adeno-associated virus (AAV).
VaxDome is a company developing a noninvasive vaccine that can be used regardless of mutations. The two companies aim to develop vaccines that prevent various viral infectious diseases and lung cancer by leveraging antigen-independent hybrid vaccine technology. They also plan to develop a vaccine for intranasal administration by rapidly converting influenza virus strains.
Pol Kim, CEO of Matica Biotechnology, said, "VaxDome's hybrid technology has the potential to be applied to the treatment and prevention of viral infections across various diseases," adding, "We will actively support the candidate's clinical entry."
Detchu Christopher Tang, CEO of VaxDome, said, "We chose Matica Biotechnology because it can carry out the entire manufacturing process in one place, from development to analytics and GMP production," adding, "We expect to accelerate clinical entry by leveraging the Texas CDMO facility."
In 2022, Matica Biotechnology built Korea's first CGT CDMO production facility in College Station, Texas, and is expanding orders based on its proprietary cell line platform "MatiMax" and its process and analytical development capabilities.